The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors

The use of EGFR inhibitors on oral squamous cell carcinoma (OSCC) as monotherapy yielded modest clinical outcomes and therefore would benefit from biomarkers that could predict which patient subsets are likely to respond. Here, we determined the efficacy of erlotinib in OSCC cell lines, and by compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hui Mei, Kelly, Gregory Michael, Zainal, Nur Syafinaz, Yee, Pei San, Fadlullah, Muhammad Zaki Hidayatullah, Lee, Bernard Kok Bang, Gan, Chai Phei, Patel, Vyomesh, Cheong, Sok Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382785/
https://www.ncbi.nlm.nih.gov/pubmed/30787334
http://dx.doi.org/10.1038/s41598-019-38742-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382785/
https://www.ncbi.nlm.nih.gov/pubmed/30787334
http://dx.doi.org/10.1038/s41598-019-38742-0

Ejemplares similares